Details of the Drug Combinations

General Information of This Drug (ID: DMPDW6T)

Drug Name
Epirubicin   DMPDW6T
Synonyms
Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1142 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Epirubicin DCOZMKA ABIRATERONE Astrocytoma (Cell Line: U251) [2]
ABIRATERONE + Epirubicin DCLYZ88 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [2]
ABIRATERONE + Epirubicin DCHAZZT ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
ABIRATERONE + Epirubicin DCO0OVH ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
ABIRATERONE + Epirubicin DCSQ42T ABIRATERONE Glioma (Cell Line: SF-539) [2]
ABIRATERONE + Epirubicin DC35RMN ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [2]
ABIRATERONE + Epirubicin DC8WV02 ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [2]
ABIRATERONE + Epirubicin DCMUSL3 ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [3]
ABIRATERONE + Epirubicin DC7YNTK ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
ABIRATERONE + Epirubicin DCRHR4Z ABIRATERONE Adenocarcinoma (Cell Line: DU-145) [4]
ABIRATERONE + Epirubicin DCYCF1L ABIRATERONE Adenocarcinoma (Cell Line: A549) [4]
ABIRATERONE + Epirubicin DCAVXZV ABIRATERONE Adenocarcinoma (Cell Line: NCIH23) [4]
ABIRATERONE + Epirubicin DCYSTSD ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
ABIRATERONE + Epirubicin DC9K1UM ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
ABIRATERONE + Epirubicin DCLG7D4 ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [4]
ABIRATERONE + Epirubicin DC8ULBU ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [4]
ABIRATERONE + Epirubicin DCBDAKJ ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [4]
ABIRATERONE + Epirubicin DCRNCUL ABIRATERONE Malignant melanoma (Cell Line: UACC62) [4]
ABIRATERONE + Epirubicin DCKH16Q ABIRATERONE Melanoma (Cell Line: UACC-257) [4]
ABIRATERONE + Epirubicin DC99MB4 ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
ABIRATERONE + Epirubicin DC8TFT4 ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
ABIRATERONE + Epirubicin DC4J8UD ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Crizotinib + Epirubicin DCPCONN Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [2]
Crizotinib + Epirubicin DC6WDN7 Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Epirubicin DC8LF53 Crizotinib Amelanotic melanoma (Cell Line: M14) [2]
Crizotinib + Epirubicin DCFSTQV Crizotinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Epirubicin DCD527H Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Crizotinib + Epirubicin DCIUO2Y Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [2]
Crizotinib + Epirubicin DC60HAJ Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [2]
Crizotinib + Epirubicin DCRSUTD Crizotinib Glioma (Cell Line: SF-539) [2]
Crizotinib + Epirubicin DC4IQB6 Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Crizotinib + Epirubicin DC4ZNSR Crizotinib Lung adenocarcinoma (Cell Line: HOP-62) [2]
Crizotinib + Epirubicin DCXIWF3 Crizotinib Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + Epirubicin DC84ONC Crizotinib Melanoma (Cell Line: UACC-257) [2]
Crizotinib + Epirubicin DCTW6ZC Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Crizotinib + Epirubicin DC488S2 Crizotinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Crizotinib + Epirubicin DCO05AN Crizotinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Crizotinib + Epirubicin DCBFSJ0 Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Epirubicin DC3XL78 Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Crizotinib + Epirubicin DCADJTY Crizotinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Crizotinib + Epirubicin DCJUULH Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Mechlorethamine DC6CN26 Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + Mechlorethamine DC9LSPA Mechlorethamine Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Pentostatin DCCTR3D Pentostatin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Pentostatin DCUYAUC Pentostatin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Pentostatin DCXP62Q Pentostatin Glioma (Cell Line: SF-268) [2]
Epirubicin + Pentostatin DCCPOOX Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Pentostatin DC713GC Pentostatin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Fulvestrant DCA3Y4Z Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Fulvestrant DCCQ53E Fulvestrant Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Fulvestrant DCJNTWP Fulvestrant Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Fulvestrant DCQNNWN Fulvestrant Glioma (Cell Line: SF-268) [2]
Epirubicin + Gefitinib DCQEO3O Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Gefitinib DCH6SXM Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Gefitinib DCL30CY Gefitinib Astrocytoma (Cell Line: U251) [2]
Epirubicin + Gefitinib DCH4EDP Gefitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Gefitinib DCY6J8K Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Gefitinib DCBA2L2 Gefitinib Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Gefitinib DCHDQX3 Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Gefitinib DCGOPVG Gefitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Gefitinib DC6Y91Y Gefitinib Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Gefitinib DCGLSN4 Gefitinib Glioma (Cell Line: SF-295) [2]
Epirubicin + Gefitinib DCSE9H5 Gefitinib Glioma (Cell Line: SF-539) [2]
Epirubicin + Gefitinib DCOLS8Y Gefitinib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Ruxolitinib DCLKWG5 Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Ruxolitinib DC5P7FW Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Ruxolitinib DCYHN9Z Ruxolitinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Ruxolitinib DCGT9GO Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Hepzato DCC555H Hepzato Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Hepzato DC7ZCA6 Hepzato Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Hepzato DC4GEG7 Hepzato Glioma (Cell Line: SF-295) [2]
Epirubicin + Hepzato DCPREJV Hepzato Glioma (Cell Line: SF-268) [2]
Epirubicin + Ixabepilone DC3SEXX Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Dactinomycin DCQ7GLF Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + Dactinomycin DCWP350 Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Dactinomycin DC26GXQ Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Dactinomycin DCDLIAR Dactinomycin Astrocytoma (Cell Line: U251) [2]
Epirubicin + Dactinomycin DCQAOT7 Dactinomycin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Dactinomycin DCZBEFV Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Dactinomycin DCBGDTQ Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Dactinomycin DCKYWVV Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Dactinomycin DCBR0Z6 Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Dactinomycin DC8TM70 Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Dactinomycin DC2MP86 Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Dactinomycin DC8J7WK Dactinomycin Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Dactinomycin DCQD6D2 Dactinomycin Glioma (Cell Line: SF-268) [2]
Epirubicin + Dactinomycin DCNBB97 Dactinomycin Glioma (Cell Line: SF-295) [2]
Epirubicin + Dactinomycin DCOWLTC Dactinomycin Glioma (Cell Line: SF-539) [2]
Epirubicin + Dactinomycin DCF4VCT Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Dactinomycin DCY5RT6 Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Dactinomycin DCEOI7Y Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + DFN-15 DC8FKKH DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + DFN-15 DCT94J0 DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + DFN-15 DCFY8CM DFN-15 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + DFN-15 DCR5W5M DFN-15 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + DFN-15 DC2VOX3 DFN-15 Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + DFN-15 DC130R4 DFN-15 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + DFN-15 DC6E1RE DFN-15 Glioma (Cell Line: SF-268) [2]
Epirubicin + DFN-15 DCHUA1O DFN-15 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + DFN-15 DCWSUIY DFN-15 Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Lapatinib DC3SSV2 Lapatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Lapatinib DCDF8EJ Lapatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Lapatinib DCOR3HF Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Lapatinib DCN2TNA Lapatinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Lapatinib DCQ8QQ0 Lapatinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Lapatinib DCGX5L0 Lapatinib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Crizotinib DC57WDH Crizotinib Astrocytoma (Cell Line: U251) [2]
Epirubicin + Crizotinib DCEUXGM Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Crizotinib DCY2O35 Crizotinib Glioma (Cell Line: SF-539) [2]
Epirubicin + Cyclophosphamide DC68VB0 Cyclophosphamide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Cyclophosphamide DC3OQEU Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Cyclophosphamide DC0JQYI Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Vismodegib DCICQPU Vismodegib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + Vismodegib DCUDR0G Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Vismodegib DCDFIII Vismodegib Astrocytoma (Cell Line: U251) [2]
Epirubicin + Vismodegib DC4JXSH Vismodegib Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Vismodegib DCMM5WM Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Vismodegib DCACLXV Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Vismodegib DC1T0BM Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Vismodegib DCHM4KR Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Vismodegib DCRVR5W Vismodegib Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Vismodegib DC7TQES Vismodegib Glioma (Cell Line: SF-539) [2]
Epirubicin + Vismodegib DCW1FE0 Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Vismodegib DCOMZ6X Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Vismodegib DCIBMUY Vismodegib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Isoniazid DC0HA8Q Isoniazid Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Isoniazid DCR3RWS Isoniazid Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Isoniazid DCJVUR0 Isoniazid Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Isoniazid DCMHZKG Isoniazid Glioma (Cell Line: SF-268) [2]
Epirubicin + Vemurafenib DCFVGR5 Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + Vemurafenib DCY21CB Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Vemurafenib DCV1ZVB Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Vemurafenib DCLIIXU Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Vemurafenib DC5XQX3 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Vemurafenib DCMDNSH Vemurafenib Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Vemurafenib DC3I2P9 Vemurafenib Glioma (Cell Line: SF-539) [2]
Epirubicin + Vemurafenib DCMLO4I Vemurafenib Glioma (Cell Line: SF-268) [2]
Epirubicin + Vemurafenib DC23Y76 Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Vemurafenib DCNB1E1 Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Vemurafenib DC16W88 Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Lenalidomide DCGSB47 Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Plicamycin DCXJMTQ Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Plicamycin DC1XM5T Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Plicamycin DCOOD4P Plicamycin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Plicamycin DC6GGW1 Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Plicamycin DCTJQJ3 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Plicamycin DCGJFPH Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Plicamycin DCZXV64 Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Plicamycin DCWDMWY Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Plicamycin DCQ8BYR Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Plicamycin DC3NJFE Plicamycin Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Plicamycin DC4HPZP Plicamycin Glioma (Cell Line: SF-268) [2]
Epirubicin + Plicamycin DC5STQ8 Plicamycin Glioma (Cell Line: SF-295) [2]
Epirubicin + Plicamycin DCZXQ2Y Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Plicamycin DCM5QGF Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Plicamycin DCHWXFQ Plicamycin Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Plicamycin DC4WAR4 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Nilotinib DCXR942 Nilotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Nilotinib DCQ9I1C Nilotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Nilotinib DCRGVK6 Nilotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Nilotinib DCSZOHW Nilotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Nilotinib DC06YTC Nilotinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Nilotinib DCVD9SH Nilotinib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Thioguanine DCJL2RX Thioguanine Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Thioguanine DCND261 Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Thioguanine DCN1Q9Q Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Thioguanine DC12B8P Thioguanine Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Thioguanine DC9OVS2 Thioguanine Glioma (Cell Line: SF-295) [2]
Epirubicin + Thioguanine DCKTWBY Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Thioguanine DCDFK7K Thioguanine Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Triapine DCMQ7B1 Triapine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + ABIRATERONE DCMPZ0G ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + ABIRATERONE DCWPOH4 ABIRATERONE Astrocytoma (Cell Line: U251) [2]
Epirubicin + ABIRATERONE DCQZQ2S ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + ABIRATERONE DC6OOIS ABIRATERONE Glioma (Cell Line: SF-539) [2]
Epirubicin + ABIRATERONE DCSD7GF ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + ABIRATERONE DCD3HXM ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Amonafide DC5OBCV Amonafide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Pralatrexate DCP6T5N Pralatrexate Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Pralatrexate DCQ58D9 Pralatrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Pralatrexate DC3GDFQ Pralatrexate Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Pralatrexate DC54SDH Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Pralatrexate DCJNIMS Pralatrexate Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Terameprocol DC45E43 Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Terameprocol DCYDRAP Terameprocol Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Terameprocol DCCR3AD Terameprocol Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Terameprocol DCT23YI Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Terameprocol DCQ7X6W Terameprocol Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Terameprocol DC698QN Terameprocol Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Terameprocol DC1NSND Terameprocol Glioma (Cell Line: SF-268) [2]
Epirubicin + SCH 727965 DCK6EEZ SCH 727965 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + SCH 727965 DCPS529 SCH 727965 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Ifosfamide DC681NW Ifosfamide Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Ifosfamide DC5GJ53 Ifosfamide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Ifosfamide DCOETNI Ifosfamide Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Ifosfamide DC1YDML Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Ifosfamide DCTMHOE Ifosfamide Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Dexrazoxane DC6QYDA Dexrazoxane Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Dexrazoxane DCRBVMU Dexrazoxane Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Dexrazoxane DCO8EMY Dexrazoxane Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Dexrazoxane DCFMNZ7 Dexrazoxane Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Docetaxel DCUFO0R Docetaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Docetaxel DC70BUX Docetaxel Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Raloxifene DC5BLYB Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Raloxifene DCPKQK2 Raloxifene Astrocytoma (Cell Line: U251) [2]
Epirubicin + Raloxifene DCNP7SE Raloxifene Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Raloxifene DCFB4XA Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Raloxifene DC765AH Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Raloxifene DCXYC66 Raloxifene Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Raloxifene DCFBPQ4 Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Raloxifene DCRA6JR Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Raloxifene DC5JB0J Raloxifene Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Raloxifene DCK3QFE Raloxifene Glioma (Cell Line: SF-268) [2]
Epirubicin + Raloxifene DCR5BN8 Raloxifene Glioma (Cell Line: SF-539) [2]
Epirubicin + Raloxifene DCA35T3 Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Bendamustine hydrochloride DCUZ1XD Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Bendamustine hydrochloride DC4OY03 Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Bendamustine hydrochloride DC4C3M0 Bendamustine hydrochloride Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Trifluridine DCU3Y8P Trifluridine Glioma (Cell Line: SF-539) [2]
Epirubicin + Trifluridine DCEIUUR Trifluridine Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Sirolimus DC88J3K Sirolimus Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Sirolimus DCEZF6A Sirolimus Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Letrozole DCTRRTW Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Letrozole DCXHEYT Letrozole Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Letrozole DCGWXTI Letrozole Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Letrozole DCVMN6Z Letrozole Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Letrozole DC44MPA Letrozole Glioma (Cell Line: SF-268) [2]
Epirubicin + Letrozole DCVXTNE Letrozole Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Mitomycin DC6L1AF Mitomycin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Mitomycin DCP4CF9 Mitomycin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + SY-1425 DC1M0E6 SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Epirubicin + SY-1425 DCDVFYZ SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + SY-1425 DCWBAM2 SY-1425 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + SY-1425 DCRUQ04 SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + SY-1425 DCWUH8A SY-1425 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + SY-1425 DCSTMJI SY-1425 Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + SY-1425 DC33ABV SY-1425 Glioma (Cell Line: SF-268) [2]
Epirubicin + SY-1425 DCKYM26 SY-1425 Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Uracil mustard DCOKQUD Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Uracil mustard DC273K8 Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Uracil mustard DCCXO47 Uracil mustard Glioma (Cell Line: SF-295) [2]
Epirubicin + Vincristine DCHYXOW Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Vincristine DCN0O2C Vincristine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Vincristine DC8S1V4 Vincristine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Vincristine DC13ZJD Vincristine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Vincristine DC1IA7L Vincristine Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Vincristine DCOYF5D Vincristine Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Arfolitixorin DC5A2LG Arfolitixorin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Arfolitixorin DCOY9NK Arfolitixorin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Arfolitixorin DCD41R1 Arfolitixorin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Arfolitixorin DCL4CJO Arfolitixorin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Arfolitixorin DCWPZCF Arfolitixorin Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Arfolitixorin DCTDVGI Arfolitixorin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + BIO-300 DCE6DIK BIO-300 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Altretamine DCX6A57 Altretamine Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Altretamine DCODT33 Altretamine Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + TEM DCJ3N74 TEM Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + TEM DCNCA6D TEM Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + TEM DCEB43V TEM Glioma (Cell Line: SF-268) [2]
Epirubicin + JNK-IN-8 DC86P9G JNK-IN-8 Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Idarubicin DCU56D5 Idarubicin Glioblastoma? (Cell Line: T98G) [2]
Epirubicin + Indazole derivative 5 DCMFL7Y Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Indazole derivative 5 DCWPWDO Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Indazole derivative 5 DCFXP8Z Indazole derivative 5 Glioma (Cell Line: SF-539) [2]
Epirubicin + Indazole derivative 5 DCXPV6K Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Indazole derivative 5 DCQ01PE Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Imatinib DCCUUCL Imatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Imatinib DCBAXMD Imatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Imatinib DCLXZCK Imatinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Imatinib DC4PGXS Imatinib Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Bleomycin DCXR7T1 Bleomycin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Bleomycin DCC5DAG Bleomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Bleomycin DCTQS27 Bleomycin Glioma (Cell Line: SF-539) [2]
Epirubicin + Bleomycin DCHVUCA Bleomycin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Bleomycin DC02C0S Bleomycin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Bortezomib DCHXC2I Bortezomib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Bortezomib DCPNIBM Bortezomib Glioma (Cell Line: SF-268) [2]
Epirubicin + Anastrozole DC9HD8S Anastrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Anastrozole DCINRQ2 Anastrozole Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Anastrozole DCB27HE Anastrozole Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Dacarbazine DCWLZVN Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Dacarbazine DCCTSYB Dacarbazine Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Dacarbazine DCC5KYA Dacarbazine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Dacarbazine DCJ7EDC Dacarbazine Glioma (Cell Line: SF-295) [2]
Epirubicin + Dacarbazine DCE8M4I Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Dacarbazine DCWTWSB Dacarbazine Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Valrubicin DCL8ZOM Valrubicin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Valrubicin DC5YUHK Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Valrubicin DC0V13Q Valrubicin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Topotecan DCBASI9 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Topotecan DC8HZFB Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Topotecan DCTRP8V Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Topotecan DCWRLF5 Topotecan Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Cabazitaxel DC5YBE5 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Cabazitaxel DCWH56J Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Cisplatin DCIDHLH Cisplatin Anaplastic large cell lymphoma (Cell Line: SR) [2]
Epirubicin + Cisplatin DC93PE3 Cisplatin Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Cisplatin DCR5054 Cisplatin Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Cisplatin DCVU9EX Cisplatin Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Cisplatin DCUBM19 Cisplatin Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Cisplatin DCSKAYD Cisplatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Cisplatin DCLBAZL Cisplatin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Vandetanib DC98RZE Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Vandetanib DC38THL Vandetanib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Vandetanib DCHSKMU Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Sorafenib DC71BO8 Sorafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Sorafenib DCTP4FF Sorafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Sorafenib DCLXMBZ Sorafenib Glioma (Cell Line: SF-539) [2]
Epirubicin + ER819762 DCBCFMO ER819762 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Azacitidine DCKZDSG Azacitidine Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Pomalidomide DCAHPGN Pomalidomide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Pomalidomide DCYT3WH Pomalidomide Astrocytoma (Cell Line: SNB-19) [2]
Epirubicin + Pomalidomide DCNZ6XD Pomalidomide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Pomalidomide DC4TGFI Pomalidomide Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Pomalidomide DCWUG1R Pomalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Pomalidomide DCHTSZD Pomalidomide Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Pomalidomide DCPEMOD Pomalidomide Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Epirubicin + Pomalidomide DC29C7Q Pomalidomide Glioma (Cell Line: SF-268) [2]
Epirubicin + Vinflunine DC19CJ0 Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Vinflunine DC2GSOI Vinflunine Glioblastoma (Cell Line: SNB-75) [2]
Epirubicin + Vinflunine DCB46RW Vinflunine Glioma (Cell Line: SF-539) [2]
Epirubicin + Vinflunine DCVNP7T Vinflunine Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Vinflunine DCFSEOG Vinflunine Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + Mercaptopurine DCEX5VS Mercaptopurine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Epirubicin + Mepacrine DCAOSPF Mepacrine Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Taxol DCOO8OO Taxol Astrocytoma (Cell Line: U251) [2]
Epirubicin + Taxol DC5CD0U Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Epirubicin + Taxol DCVQ45F Taxol Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Taxol DCYMAWR Taxol Glioma (Cell Line: SF-295) [2]
Epirubicin + Taxol DC1NAA6 Taxol Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Taxol DCZ0740 Taxol Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + PMID28870136-Compound-43 DCHV530 PMID28870136-Compound-43 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + FORMESTANE DC7AE2Z FORMESTANE Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + FORMESTANE DC0UCGB FORMESTANE Glioma (Cell Line: SF-268) [2]
Epirubicin + Aminolevulinic Acid Hydrochloride DCVTSF8 Aminolevulinic Acid Hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Estramustine DCF4PJC Estramustine Chronic myelogenous leukemia (Cell Line: K-562) [2]
Epirubicin + Estramustine DCXXNIG Estramustine Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Epirubicin + Estramustine DCFV2CW Estramustine Clear cell renal cell carcinoma (Cell Line: A498) [2]
Epirubicin + Estramustine DCUP9H4 Estramustine Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Estramustine DCKXFLQ Estramustine Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Digitoxin DCHBOX4 Digitoxin Renal cell carcinoma (Cell Line: UO-31) [2]
Epirubicin + Dasatinib DCPOUQX Dasatinib Astrocytoma (Cell Line: U251) [2]
Epirubicin + Dasatinib DCZIXL2 Dasatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Dasatinib DCTTA88 Dasatinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Mechlorethamine DC04J7X Mechlorethamine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Pentostatin DC9R313 Pentostatin Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Pentostatin DCPV0K8 Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Pentostatin DCH6ISR Pentostatin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Picoplatin DC2IGA0 Picoplatin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Picoplatin DCIBMQY Picoplatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Fulvestrant DC44OOK Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Fulvestrant DCDGKF3 Fulvestrant Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Fulvestrant DCHCHRW Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Gefitinib DCQRV6O Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Gefitinib DCP3ZUK Gefitinib Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Gefitinib DC3SX6G Gefitinib Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Gefitinib DC0STK3 Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Gefitinib DCW54JG Gefitinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Gefitinib DC8O5KI Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Ruxolitinib DCGKPSU Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Ruxolitinib DC4QV1F Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Hepzato DCQQDH3 Hepzato Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Hepzato DCM4RB6 Hepzato Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Dactinomycin DC0R8OZ Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Dactinomycin DCVMQM9 Dactinomycin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Dactinomycin DCMILK1 Dactinomycin Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Dactinomycin DCL7GRW Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Dactinomycin DCYT2JY Dactinomycin Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Dactinomycin DCPRQ28 Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Dactinomycin DCWLAGV Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Dactinomycin DCF9HP1 Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + DFN-15 DC4JW8M DFN-15 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + DFN-15 DCMCWRL DFN-15 Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + DFN-15 DCUMOMN DFN-15 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + DFN-15 DCW9DPF DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + DFN-15 DCID271 DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + DFN-15 DCTNT0E DFN-15 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Lapatinib DC32774 Lapatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Lapatinib DCU1YK4 Lapatinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Lapatinib DC0X8CP Lapatinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + PMID28460551-Compound-2 DC9F3UD PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Cyclophosphamide DCFDQ9I Cyclophosphamide Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Cyclophosphamide DCG0369 Cyclophosphamide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + LIAROZOLE DCJUC5E LIAROZOLE Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Methotrexate DC8UW7M Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Vismodegib DC6M4RI Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Vismodegib DC1OYZV Vismodegib Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Vismodegib DC0LB7N Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Vismodegib DCR994M Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Isoniazid DC1R0YC Isoniazid Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Isoniazid DCBPK86 Isoniazid Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Vemurafenib DCE6CTN Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Vemurafenib DC84ZWP Vemurafenib Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Vemurafenib DC1J7S5 Vemurafenib Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Vemurafenib DCGQ9FN Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Vemurafenib DCZO7BY Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Vemurafenib DC1UDPO Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Lenalidomide DCQVOJZ Lenalidomide Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Lenalidomide DCO4U18 Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Plicamycin DC3MMPT Plicamycin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Plicamycin DCFHZG2 Plicamycin Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Plicamycin DCS4SOO Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Plicamycin DCV7W7E Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Plicamycin DC2H8LI Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Plicamycin DCBXL01 Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Nilotinib DC9VP31 Nilotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Nilotinib DCQPFDR Nilotinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Nilotinib DCB1CPE Nilotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Thioguanine DC80TY3 Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Thioguanine DC2GF04 Thioguanine Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Thioguanine DCV6TKC Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + ABIRATERONE DC5UHDR ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + ABIRATERONE DC9US4R ABIRATERONE Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + ABIRATERONE DC0SO6P ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + 10-hydroxycamptothecin DCUEVC5 10-hydroxycamptothecin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Topetecan DC2CKQQ Topetecan Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Terameprocol DC9WIVA Terameprocol Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Terameprocol DCRIOGO Terameprocol Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Terameprocol DCBCMPC Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Terameprocol DCUYYD8 Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Ifosfamide DCUB46B Ifosfamide Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Ifosfamide DC3SQX1 Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Ifosfamide DC1YBDK Ifosfamide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Dexrazoxane DC851HP Dexrazoxane Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Dexrazoxane DCNBMU2 Dexrazoxane Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Raloxifene DCZ3HIC Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Raloxifene DC9WT79 Raloxifene Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Raloxifene DCJYQ34 Raloxifene Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Raloxifene DCZAIG7 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Raloxifene DC1KGEM Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Raloxifene DC3MYDU Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Trifluridine DCH94DJ Trifluridine Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Sirolimus DCJI1QX Sirolimus Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Sirolimus DC71ZJU Sirolimus Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Letrozole DCPYJ3T Letrozole Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Letrozole DC6U98C Letrozole Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Mitomycin DCQERBC Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Mitomycin DC9WQ4R Mitomycin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Mitomycin DC2ODP5 Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Mitomycin DCSBEIK Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + SY-1425 DCHDUAC SY-1425 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + SY-1425 DCFTIYS SY-1425 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Uracil mustard DCHRSPZ Uracil mustard Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Arfolitixorin DCQR7YQ Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Arfolitixorin DC7DECE Arfolitixorin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Arfolitixorin DCO1KGX Arfolitixorin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + BIO-300 DCYVVQI BIO-300 Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Altretamine DCPIKW2 Altretamine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + TEM DCWP62Q TEM Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + TEM DCIIE1W TEM Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + JNK-IN-8 DCF2WAF JNK-IN-8 Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Idarubicin DC7318N Idarubicin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Idarubicin DCKWUAU Idarubicin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Idarubicin DC62KEV Idarubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Indazole derivative 5 DC3665Q Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Indazole derivative 5 DCW3078 Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Epirubicin + Imatinib DCOYKJ6 Imatinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Imatinib DC64ZEF Imatinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Bleomycin DCX0AH2 Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Bleomycin DCQYJR1 Bleomycin Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Bleomycin DCLSNJB Bleomycin Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Bortezomib DCT9VGM Bortezomib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Dacarbazine DCR1AT8 Dacarbazine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Dacarbazine DCO4FUQ Dacarbazine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Dacarbazine DCH2ZSS Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Valrubicin DC6CFTQ Valrubicin Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Valrubicin DC88HXA Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Valrubicin DCK65DA Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Topotecan DC27WT2 Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Topotecan DC9YDRI Topotecan Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Topotecan DCNJM9M Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Cisplatin DCD3IYU Cisplatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Epirubicin + Cisplatin DC9Z25M Cisplatin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Cisplatin DC9ED2P Cisplatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Vandetanib DC4I39Q Vandetanib Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Vandetanib DC46DPE Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + ER819762 DCNDEW8 ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Azacitidine DCC1U8B Azacitidine Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Pomalidomide DCIFIFH Pomalidomide Carcinoma (Cell Line: RXF 393) [3]
Epirubicin + Pomalidomide DC30ATM Pomalidomide Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Pomalidomide DC47Z24 Pomalidomide Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Pomalidomide DCEXUTT Pomalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Pomalidomide DCOR888 Pomalidomide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + PMID28870136-Compound-43 DCEQL87 PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + FORMESTANE DCYDDCR FORMESTANE Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + FORMESTANE DCOAH4G FORMESTANE Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Estramustine DC9FQ72 Estramustine Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Estramustine DCDR9DM Estramustine Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Estramustine DCM0W2T Estramustine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Estramustine DC28FAJ Estramustine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Estramustine DCF7JPA Estramustine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Digitoxin DCXVUKE Digitoxin Carcinoma (Cell Line: MCF7) [3]
Epirubicin + Digitoxin DCSZ9UG Digitoxin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Dasatinib DC37TWH Dasatinib Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Dasatinib DCKAVI2 Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Epirubicin + Mechlorethamine DCCP669 Mechlorethamine Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Mechlorethamine DCSRTVC Mechlorethamine Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Mechlorethamine DCVQA2X Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Mechlorethamine DC33YRT Mechlorethamine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Pentostatin DCU7G9D Pentostatin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Pentostatin DCAD8B0 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Pentostatin DCW4260 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Pentostatin DCSFQ2N Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Pentostatin DCS772O Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Pentostatin DCOV7T7 Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Pentostatin DCBJC6X Pentostatin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Pentostatin DCXURD1 Pentostatin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Pentostatin DC7XJKS Pentostatin Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Pentostatin DCCR3KI Pentostatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Picoplatin DCHYX1Q Picoplatin Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Picoplatin DCM4ULB Picoplatin Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Fulvestrant DCRM4HG Fulvestrant Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Fulvestrant DCYX838 Fulvestrant Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Fulvestrant DC1O3DY Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Fulvestrant DC56NNV Fulvestrant Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Fulvestrant DCNU8VE Fulvestrant Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Fulvestrant DCTWIRF Fulvestrant Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Fulvestrant DCC6BHG Fulvestrant Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Gefitinib DCA93RG Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Gefitinib DCEAFVV Gefitinib Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Gefitinib DC4AAYP Gefitinib Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Gefitinib DCSNWQ2 Gefitinib Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Gefitinib DCV0B5O Gefitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Gefitinib DC4YVAG Gefitinib Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Gefitinib DC9UFD0 Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Gefitinib DCJXG4I Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Gefitinib DCBDT3T Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Gefitinib DC76Y0N Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Gefitinib DCCEQMI Gefitinib Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Gefitinib DCBTSLH Gefitinib Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Gefitinib DCDBPLA Gefitinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Gefitinib DCZVB4U Gefitinib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Gefitinib DC4FQG9 Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Gefitinib DCTLOEV Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Gefitinib DCYBXDG Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Gefitinib DCBUDQ1 Gefitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Ruxolitinib DCMMTBJ Ruxolitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Ruxolitinib DC1GCN6 Ruxolitinib Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Ruxolitinib DC6LUMS Ruxolitinib Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Ruxolitinib DCMCNP2 Ruxolitinib Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Ruxolitinib DCTB8V4 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Ruxolitinib DC1X09O Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Ruxolitinib DCU4U2O Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Ruxolitinib DC5I6J1 Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Ruxolitinib DC8UW91 Ruxolitinib Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Ruxolitinib DC8U3OK Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Ruxolitinib DCT65LB Ruxolitinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Ruxolitinib DCC67VS Ruxolitinib Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Hepzato DC2HZPI Hepzato Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Hepzato DC21K16 Hepzato Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Hepzato DCFUUU0 Hepzato Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Hepzato DCACU1H Hepzato Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Hepzato DCB19MS Hepzato Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Hepzato DCS4NFC Hepzato Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Hepzato DC75D1Y Hepzato Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Hepzato DC8KU8I Hepzato Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Ixabepilone DC3UL71 Ixabepilone Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Dactinomycin DCCKOFG Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Dactinomycin DCFXN48 Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Dactinomycin DCIDM5C Dactinomycin Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Dactinomycin DC9697Y Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Dactinomycin DCXFA05 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Epirubicin + Dactinomycin DCOUTL7 Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Dactinomycin DCUCLXL Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Dactinomycin DC5O446 Dactinomycin Adenocarcinoma (Cell Line: SW-620) [4]
Epirubicin + Dactinomycin DC5J0ER Dactinomycin Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Dactinomycin DCKCDE7 Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Dactinomycin DCPUX87 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Dactinomycin DC9FHYE Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Dactinomycin DCXFM4T Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Dactinomycin DCH7TG6 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Dactinomycin DCJR6IP Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Dactinomycin DCBQOER Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Dactinomycin DC8L40Q Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Dactinomycin DCS8S1F Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Dactinomycin DC4GP1E Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Dactinomycin DC6LXI5 Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Dactinomycin DCXO6JQ Dactinomycin Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Dactinomycin DCGWQC2 Dactinomycin Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Dactinomycin DCNAG66 Dactinomycin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Dactinomycin DCQIE9K Dactinomycin Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Dactinomycin DCKJM2P Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Dactinomycin DCYJNC8 Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Dactinomycin DCXZL50 Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Dactinomycin DC9YGY6 Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Dactinomycin DC96JS4 Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Dactinomycin DC6M8HP Dactinomycin Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + DFN-15 DC21SFI DFN-15 Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + DFN-15 DCNM0WO DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + DFN-15 DCPW6SL DFN-15 Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + DFN-15 DC0A5D5 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + DFN-15 DC6V772 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + DFN-15 DC3UVSE DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + DFN-15 DCOOZ90 DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + DFN-15 DCJYP37 DFN-15 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + DFN-15 DCYPERS DFN-15 Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + DFN-15 DC7U70M DFN-15 Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + DFN-15 DCO5JLC DFN-15 Melanoma (Cell Line: UACC-257) [4]
Epirubicin + DFN-15 DCINDT9 DFN-15 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + DFN-15 DCEGT94 DFN-15 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + DFN-15 DCCIA4X DFN-15 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + DFN-15 DCRBIWD DFN-15 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Lapatinib DC88SAQ Lapatinib Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Lapatinib DCXI5IP Lapatinib Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Lapatinib DCEOB69 Lapatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Lapatinib DCP1M5U Lapatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Lapatinib DC6A6EP Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Lapatinib DCHED89 Lapatinib Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Lapatinib DC46TBK Lapatinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Lapatinib DCYD3FY Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Lapatinib DC097BP Lapatinib Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + PMID28460551-Compound-2 DCU33Y2 PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + PMID28460551-Compound-2 DC3BTUQ PMID28460551-Compound-2 Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + PMID28460551-Compound-2 DCC20ZT PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + PMID28460551-Compound-2 DCS8X50 PMID28460551-Compound-2 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Crizotinib DCXOM1B Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Epirubicin + Crizotinib DCN744Q Crizotinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Cyclophosphamide DCJEQRG Cyclophosphamide Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Cyclophosphamide DCIAOL6 Cyclophosphamide Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Cyclophosphamide DC0D43T Cyclophosphamide Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Cyclophosphamide DC0WB3Q Cyclophosphamide Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Cyclophosphamide DCGJEEH Cyclophosphamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + LIAROZOLE DCPPMLQ LIAROZOLE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Methotrexate DCGJT3I Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Vismodegib DCZ0JLN Vismodegib Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Vismodegib DCIGY64 Vismodegib Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Vismodegib DCFHAE3 Vismodegib Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Vismodegib DCNNEMO Vismodegib Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Vismodegib DCHJM4G Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Vismodegib DC5EERQ Vismodegib Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Vismodegib DCT77DF Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Vismodegib DCLUXMS Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Vismodegib DC857WK Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Vismodegib DC050O3 Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Vismodegib DC2DO38 Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Vismodegib DC9XHBT Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Vismodegib DCSOR6K Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Vismodegib DC6FE0Q Vismodegib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Vismodegib DCPMVJ3 Vismodegib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Vismodegib DCH9UHL Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Isoniazid DCOV6KY Isoniazid Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Isoniazid DC90KMW Isoniazid Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Isoniazid DC6QYWN Isoniazid Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Isoniazid DCLLB4H Isoniazid High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Isoniazid DCY519Z Isoniazid Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Isoniazid DCO0N59 Isoniazid Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Isoniazid DC39CLU Isoniazid Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Isoniazid DCT6ZO4 Isoniazid Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Vemurafenib DCNF5AN Vemurafenib Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Vemurafenib DCKGOTS Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Vemurafenib DC0GSVV Vemurafenib Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Vemurafenib DCUYKWT Vemurafenib Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Vemurafenib DCGK8GQ Vemurafenib Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Vemurafenib DCZ70G5 Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Vemurafenib DC292NL Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Vemurafenib DC6HE7H Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Epirubicin + Vemurafenib DCXJOGL Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Vemurafenib DCM88G8 Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Vemurafenib DCMRG5B Vemurafenib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Vemurafenib DCWVMLO Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Vemurafenib DCMLCJE Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Vemurafenib DCQDCZ6 Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Vemurafenib DC65UAX Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Vemurafenib DCNT563 Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Vemurafenib DC5DQQI Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Vemurafenib DCFUFG3 Vemurafenib Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Lenalidomide DCHOGJ6 Lenalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Plicamycin DCYYID2 Plicamycin Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Plicamycin DCUJ7XR Plicamycin Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Plicamycin DCYEWYY Plicamycin Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Plicamycin DCHEJ7P Plicamycin Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Plicamycin DCU9PTZ Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Plicamycin DCC58MZ Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Plicamycin DCQGSCU Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Plicamycin DCN5R9V Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Plicamycin DC8GQNX Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Plicamycin DCMSPFZ Plicamycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Plicamycin DCK73UI Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Plicamycin DC1OVDB Plicamycin Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Plicamycin DCXRK7Y Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Plicamycin DCOER6L Plicamycin Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Plicamycin DCHXUCR Plicamycin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Plicamycin DCRYPZD Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Plicamycin DC8X13Q Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Plicamycin DCIIJJU Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Nilotinib DCPERFJ Nilotinib Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Nilotinib DCKSHZ3 Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Nilotinib DCSP3LJ Nilotinib Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Nilotinib DC5HPSB Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Nilotinib DCM3X3V Nilotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Nilotinib DCXS4LX Nilotinib Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Nilotinib DC5X111 Nilotinib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Nilotinib DC6PCLO Nilotinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Nilotinib DCQNE9P Nilotinib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Nilotinib DC6IPWP Nilotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Nilotinib DCZF40V Nilotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Nilotinib DCERP20 Nilotinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Nilotinib DCDG5HP Nilotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Nilotinib DCXIFZT Nilotinib Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Thioguanine DCFZ9O2 Thioguanine Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Thioguanine DC48K9P Thioguanine Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Triapine DCYAJ2B Triapine Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Triapine DCMOY52 Triapine Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Triapine DCY16WX Triapine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Triapine DCU38LP Triapine Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + ABIRATERONE DCSDCOA ABIRATERONE Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + ABIRATERONE DC0BC7O ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + ABIRATERONE DCZCUTV ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + ABIRATERONE DCSCXLM ABIRATERONE Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + ABIRATERONE DC2T7YQ ABIRATERONE Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + ABIRATERONE DCZGKK3 ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + ABIRATERONE DCPSWIZ ABIRATERONE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + ABIRATERONE DC4V8VU ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + 10-hydroxycamptothecin DCRNGYH 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Pralatrexate DCE5X13 Pralatrexate Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Pralatrexate DCA7CN4 Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Pralatrexate DC6MFOD Pralatrexate Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Terameprocol DCDG6SR Terameprocol Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Terameprocol DCZDGFH Terameprocol Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Terameprocol DCDN7IS Terameprocol Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Terameprocol DC122YH Terameprocol Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Terameprocol DCV2ALU Terameprocol Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Terameprocol DC0ZUPZ Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Terameprocol DC3IDWP Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Terameprocol DCWETAX Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Terameprocol DCGHDII Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Terameprocol DC6RZ6D Terameprocol Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Terameprocol DC32I6O Terameprocol Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Terameprocol DCKC3E6 Terameprocol Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Terameprocol DCD8F5I Terameprocol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + SCH 727965 DCERQ1P SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + SCH 727965 DC4O45C SCH 727965 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Epirubicin + SCH 727965 DC8Y1MR SCH 727965 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + SCH 727965 DCR0O1K SCH 727965 Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + SCH 727965 DCZW7U1 SCH 727965 Melanoma (Cell Line: UACC-257) [4]
Epirubicin + SCH 727965 DC6L4YH SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Ifosfamide DC8W80C Ifosfamide Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Ifosfamide DCXBPVP Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Ifosfamide DC8N4FO Ifosfamide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Dexrazoxane DCK86Q5 Dexrazoxane Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Dexrazoxane DC15D1Q Dexrazoxane Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Dexrazoxane DC0JLOQ Dexrazoxane High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Dexrazoxane DC02E2A Dexrazoxane Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Dexrazoxane DCUL30L Dexrazoxane Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Docetaxel DCX8DG2 Docetaxel Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Docetaxel DCJ0Q14 Docetaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Docetaxel DCD6AAT Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Docetaxel DCFNDE5 Docetaxel Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Raloxifene DCT5MUT Raloxifene Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Raloxifene DCOYBGJ Raloxifene Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Raloxifene DCTRI17 Raloxifene Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Raloxifene DCRN778 Raloxifene Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Raloxifene DCKB5F4 Raloxifene Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Raloxifene DC8MML8 Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Raloxifene DCVLP0T Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Raloxifene DCR0NA6 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Raloxifene DCQ2G7Q Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Raloxifene DC4U5YT Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Raloxifene DCP6HMO Raloxifene Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Raloxifene DCQY5WX Raloxifene Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Raloxifene DCTTKHL Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Raloxifene DC9BX5L Raloxifene Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Raloxifene DC7C8D9 Raloxifene Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Raloxifene DCO2Y8M Raloxifene Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Raloxifene DCBJJ7J Raloxifene Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Raloxifene DCB7XBE Raloxifene Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Raloxifene DCX76WP Raloxifene Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Raloxifene DCOGO2L Raloxifene Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Raloxifene DCIGTYZ Raloxifene Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Bendamustine hydrochloride DCEZ6GD Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Bendamustine hydrochloride DCEJXAM Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Bendamustine hydrochloride DC4UQ6H Bendamustine hydrochloride Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Bendamustine hydrochloride DCLII6Z Bendamustine hydrochloride Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Bendamustine hydrochloride DCH44GA Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Bendamustine hydrochloride DC1C048 Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Trifluridine DCBYC3V Trifluridine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Sirolimus DCY8TBC Sirolimus Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Sirolimus DCYOHV0 Sirolimus Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Sirolimus DCZYKOF Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Letrozole DCQDL57 Letrozole Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Letrozole DC6X7KU Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Letrozole DCDHQCI Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Letrozole DCKH9C1 Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Letrozole DC1XUKC Letrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Letrozole DCUWSXO Letrozole Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Letrozole DCWT86F Letrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Letrozole DCT3PPQ Letrozole Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Letrozole DC9YIGW Letrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Mitomycin DCAB0ST Mitomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Mitomycin DCH59H8 Mitomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Mitomycin DCQ8OVP Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Mitomycin DCIMYU7 Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Mitomycin DCEZON7 Mitomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Mitomycin DCA6TRX Mitomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + SY-1425 DCACHRW SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + SY-1425 DCS5CYD SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + SY-1425 DC5NMBO SY-1425 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + SY-1425 DCIQLM3 SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + SY-1425 DCQDMVT SY-1425 Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + SY-1425 DCRN0KO SY-1425 Melanoma (Cell Line: UACC-257) [4]
Epirubicin + SY-1425 DC3GDEX SY-1425 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Uracil mustard DCAWD9H Uracil mustard Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Vincristine DC9JM6C Vincristine Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Vincristine DCK7YDA Vincristine Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Vincristine DCSTN8L Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Arfolitixorin DC6E73P Arfolitixorin Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Arfolitixorin DCRF6HT Arfolitixorin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Arfolitixorin DC0JGWX Arfolitixorin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + BIO-300 DCHTFOC BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + BIO-300 DCUSWYN BIO-300 Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + BIO-300 DC8XYPO BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + BIO-300 DCTTTH1 BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Altretamine DC1J7IN Altretamine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + TEM DCYHAKF TEM Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + TEM DCYB0Z8 TEM Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + TEM DCBJNFO TEM Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + TEM DC70QNA TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + TEM DCZO2JV TEM Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + TEM DCIYWUD TEM Melanoma (Cell Line: UACC-257) [4]
Epirubicin + TEM DCULZI6 TEM Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Idarubicin DC6AP70 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Idarubicin DCAVX31 Idarubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Indazole derivative 5 DCBIUQ5 Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Indazole derivative 5 DC3CAOE Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Indazole derivative 5 DCZL9WH Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Indazole derivative 5 DCRVIAO Indazole derivative 5 Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Indazole derivative 5 DC56A9F Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Indazole derivative 5 DCMK2TT Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Indazole derivative 5 DCI7DPI Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Indazole derivative 5 DCZWPQ1 Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Indazole derivative 5 DCJ9UNR Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Indazole derivative 5 DCBJKIC Indazole derivative 5 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Indazole derivative 5 DCZUYZF Indazole derivative 5 Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Indazole derivative 5 DCNDBC7 Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Indazole derivative 5 DCGA63F Indazole derivative 5 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Indazole derivative 5 DCI5VOA Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Indazole derivative 5 DCU5HQA Indazole derivative 5 Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Imatinib DCEDXWV Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Imatinib DCFQQFU Imatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Imatinib DC0HR48 Imatinib Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Imatinib DCM2QUW Imatinib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Imatinib DCUK4GM Imatinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Imatinib DCR1EHD Imatinib Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Bleomycin DCXCF0W Bleomycin Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Bleomycin DCH32OK Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Bleomycin DCEPBXU Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Bleomycin DCNSYU1 Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Bortezomib DCIR627 Bortezomib Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Bortezomib DC9DWMV Bortezomib Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Bortezomib DCXAQ0T Bortezomib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Bortezomib DCL1YI3 Bortezomib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Bortezomib DCSXSW9 Bortezomib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Bortezomib DCT6D8O Bortezomib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Bortezomib DC5A6FA Bortezomib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Bortezomib DCY5I4O Bortezomib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Anastrozole DC8SIII Anastrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Anastrozole DCZU0NJ Anastrozole Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Anastrozole DC413VI Anastrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Anastrozole DC6FVQG Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Dacarbazine DCS89RG Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Dacarbazine DC2VB5X Dacarbazine Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Dacarbazine DC9JR94 Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Dacarbazine DC0HHDE Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Dacarbazine DC36PYE Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Dacarbazine DCF7527 Dacarbazine Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Dacarbazine DCR9JRU Dacarbazine Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Valrubicin DC927ZQ Valrubicin Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Valrubicin DCM7XTC Valrubicin Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Valrubicin DCCJ93M Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Valrubicin DCJU8PU Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Valrubicin DCOWB0E Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Valrubicin DCGP8SW Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Valrubicin DC79HZD Valrubicin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Valrubicin DCNYBQ9 Valrubicin Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Valrubicin DCZDZG2 Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Topotecan DCJ8V4D Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Topotecan DCR550O Topotecan Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Topotecan DC4ZRNL Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Topotecan DCH5P6P Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Topotecan DCX26MK Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Topotecan DCITL8F Topotecan Prostate carcinoma (Cell Line: PC-3) [4]
Epirubicin + Cabazitaxel DCLBW0L Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Epirubicin + Cabazitaxel DCRXC65 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Cabazitaxel DCT4R29 Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Cabazitaxel DC4TLNV Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Cabazitaxel DC2JSC2 Cabazitaxel Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Cabazitaxel DC1CZNP Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Cisplatin DCSORVJ Cisplatin Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Cisplatin DCIJF0J Cisplatin Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Cisplatin DC2NO9N Cisplatin Adenocarcinoma (Cell Line: HT29) [4]
Epirubicin + Cisplatin DCGYVGD Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Cisplatin DC9KFLX Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Cisplatin DCFQ39F Cisplatin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Cisplatin DCC0GHK Cisplatin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Cisplatin DCUVD34 Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Cisplatin DCJB4OP Cisplatin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Cisplatin DCGQUFM Cisplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Cisplatin DC73IMB Cisplatin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Cisplatin DCZBKF3 Cisplatin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Vandetanib DCVPWWP Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Vandetanib DCP0FZB Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Vandetanib DCH07J6 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Vandetanib DCHPBXS Vandetanib Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Vandetanib DCNXNVP Vandetanib Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Vandetanib DCA1C69 Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Chlorambucil DCQNLT3 Chlorambucil Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + ER819762 DC3AIIL ER819762 Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + ER819762 DCWVZBZ ER819762 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Azacitidine DC5VT37 Azacitidine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Pomalidomide DC9C35Q Pomalidomide Adenocarcinoma (Cell Line: DU-145) [4]
Epirubicin + Pomalidomide DCKYPJT Pomalidomide Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + Pomalidomide DC957Q6 Pomalidomide Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Pomalidomide DCUL0OE Pomalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Pomalidomide DCBAKL9 Pomalidomide Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Pomalidomide DCITQRR Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Pomalidomide DCLSYCA Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Epirubicin + Pomalidomide DCU7R6F Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Pomalidomide DCXDJWC Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Pomalidomide DCRPZ07 Pomalidomide Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Pomalidomide DCDRERE Pomalidomide Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Pomalidomide DC42R3P Pomalidomide Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Pomalidomide DCRMTEP Pomalidomide Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Pomalidomide DCIF9VP Pomalidomide Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Pomalidomide DCPUDO8 Pomalidomide Melanoma (Cell Line: MALME-3M) [4]
Epirubicin + Pomalidomide DCL8Z2Y Pomalidomide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Pomalidomide DCQ5X84 Pomalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Mercaptopurine DCT7E1L Mercaptopurine Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Epirubicin + Mercaptopurine DC29B92 Mercaptopurine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Taxol DCJNULN Taxol Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Taxol DC60EOV Taxol High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Epirubicin + Taxol DCH5CY0 Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + PMID28870136-Compound-43 DC1PKWK PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + PMID28870136-Compound-43 DC1ESP2 PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + PMID28870136-Compound-43 DC1RVHK PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + PMID28870136-Compound-43 DCWTG5K PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + PMID28870136-Compound-43 DCVIJ1O PMID28870136-Compound-43 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + PMID28870136-Compound-43 DCIEJ6X PMID28870136-Compound-43 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + FORMESTANE DCO0MF2 FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [4]
Epirubicin + FORMESTANE DCOQGMG FORMESTANE Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + FORMESTANE DC80I8E FORMESTANE Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Aminolevulinic Acid Hydrochloride DCXXOX8 Aminolevulinic Acid Hydrochloride Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Epirubicin + Estramustine DC7F2C1 Estramustine Adenocarcinoma (Cell Line: HCT116) [4]
Epirubicin + Estramustine DCROF7G Estramustine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Estramustine DC2P8OZ Estramustine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Estramustine DCBEFPM Estramustine Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Estramustine DC2SO2M Estramustine Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Estramustine DCOE03I Estramustine Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Estramustine DC78QVE Estramustine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Digitoxin DCOLIIW Digitoxin Malignant melanoma (Cell Line: LOX IMVI) [4]
Epirubicin + Digitoxin DCGHYLG Digitoxin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Digitoxin DCFZDTX Digitoxin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Dasatinib DCUBK35 Dasatinib Adenocarcinoma (Cell Line: A549) [4]
Epirubicin + Dasatinib DC5S8Y6 Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Epirubicin + Dasatinib DCTS2JI Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Epirubicin + Dasatinib DC3DE2B Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Epirubicin + Dasatinib DC0UUHW Dasatinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Epirubicin + Dasatinib DCE6A3K Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Epirubicin + Dasatinib DCO2MHQ Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Epirubicin + Dasatinib DCH4RLX Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Epirubicin + Dasatinib DCS1CYY Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Epirubicin + Dasatinib DCIGDJ3 Dasatinib Prostate carcinoma (Cell Line: PC-3) [4]
Indazole derivative 5 + Epirubicin DCCOA1H Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Indazole derivative 5 + Epirubicin DC27J6K Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Indazole derivative 5 + Epirubicin DCFGXUI Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Indazole derivative 5 + Epirubicin DC8Y5KI Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Indazole derivative 5 + Epirubicin DC4LL4G Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Indazole derivative 5 + Epirubicin DC0AQH1 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Indazole derivative 5 + Epirubicin DCYZ4RD Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [4]
Indazole derivative 5 + Epirubicin DC53D9Y Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [4]
Indazole derivative 5 + Epirubicin DCHLRW4 Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [4]
Indazole derivative 5 + Epirubicin DCSFYKM Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Indazole derivative 5 + Epirubicin DCXS0OC Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Indazole derivative 5 + Epirubicin DC7VFRF Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Indazole derivative 5 + Epirubicin DCB1CTU Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Indazole derivative 5 + Epirubicin DCM0G4M Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Indazole derivative 5 + Epirubicin DC86KGD Indazole derivative 5 Melanoma (Cell Line: UACC-257) [4]
Indazole derivative 5 + Epirubicin DCJB1QB Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [4]
Indazole derivative 5 + Epirubicin DCB81B3 Indazole derivative 5 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Raloxifene + Epirubicin DCISJ8Q Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Raloxifene + Epirubicin DCD3WUE Raloxifene Astrocytoma (Cell Line: U251) [2]
Raloxifene + Epirubicin DC8H8MP Raloxifene Astrocytoma (Cell Line: SNB-19) [2]
Raloxifene + Epirubicin DC19IIG Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Raloxifene + Epirubicin DCIXE37 Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [2]
Raloxifene + Epirubicin DCABI0R Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Raloxifene + Epirubicin DC2GHEO Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Raloxifene + Epirubicin DCNLRXG Raloxifene Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Raloxifene + Epirubicin DCCUWXC Raloxifene Glioma (Cell Line: SF-268) [2]
Raloxifene + Epirubicin DC8RR3G Raloxifene Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Raloxifene + Epirubicin DCM3MWU Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Raloxifene + Epirubicin DC6ISHY Raloxifene Carcinoma (Cell Line: RXF 393) [3]
Raloxifene + Epirubicin DC5TED2 Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [3]
Raloxifene + Epirubicin DC78E56 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Raloxifene + Epirubicin DCVG7XP Raloxifene Invasive ductal carcinoma (Cell Line: T-47D) [3]
Raloxifene + Epirubicin DCCBAP2 Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [3]
Raloxifene + Epirubicin DCU5FHC Raloxifene Adenocarcinoma (Cell Line: DU-145) [4]
Raloxifene + Epirubicin DCTB825 Raloxifene Adenocarcinoma (Cell Line: OVCAR3) [4]
Raloxifene + Epirubicin DCU07RQ Raloxifene Adenocarcinoma (Cell Line: NCIH23) [4]
Raloxifene + Epirubicin DC4H0ZR Raloxifene Adenocarcinoma (Cell Line: A549) [4]
Raloxifene + Epirubicin DCLHA8D Raloxifene Adenocarcinoma (Cell Line: HCT-15) [4]
Raloxifene + Epirubicin DCVFRMR Raloxifene Adenocarcinoma (Cell Line: SW-620) [4]
Raloxifene + Epirubicin DC26C0L Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Raloxifene + Epirubicin DC9987P Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Raloxifene + Epirubicin DCFCVX6 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Raloxifene + Epirubicin DC7OLWZ Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Raloxifene + Epirubicin DCV3HX5 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Raloxifene + Epirubicin DCS0D8A Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Raloxifene + Epirubicin DCCVQCF Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Raloxifene + Epirubicin DCGQE06 Raloxifene Lung adenocarcinoma (Cell Line: EKVX) [4]
Raloxifene + Epirubicin DCMMPZF Raloxifene Malignant melanoma (Cell Line: UACC62) [4]
Raloxifene + Epirubicin DC36LNN Raloxifene Melanoma (Cell Line: SK-MEL-2) [4]
Raloxifene + Epirubicin DC11CQ8 Raloxifene Melanoma (Cell Line: MALME-3M) [4]
Raloxifene + Epirubicin DCL9J1V Raloxifene Melanoma (Cell Line: UACC-257) [4]
Raloxifene + Epirubicin DC721N3 Raloxifene Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Raloxifene + Epirubicin DCPMI71 Raloxifene Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Raloxifene + Epirubicin DCDNCIA Raloxifene Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Raloxifene + Epirubicin DC6YN7E Raloxifene Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Raloxifene + Epirubicin DCVBALQ Raloxifene Prostate carcinoma (Cell Line: PC-3) [4]
Ruxolitinib + Epirubicin DCJY38I Ruxolitinib Astrocytoma (Cell Line: U251) [2]
Ruxolitinib + Epirubicin DCJBRMD Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Ruxolitinib + Epirubicin DCHFUE6 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Ruxolitinib + Epirubicin DCT437T Ruxolitinib Glioblastoma (Cell Line: SNB-75) [2]
Ruxolitinib + Epirubicin DCYURE8 Ruxolitinib Glioma (Cell Line: SF-539) [2]
Ruxolitinib + Epirubicin DCY350T Ruxolitinib Glioma (Cell Line: SF-268) [2]
Ruxolitinib + Epirubicin DCNH4QN Ruxolitinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Ruxolitinib + Epirubicin DCVCP7F Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Ruxolitinib + Epirubicin DC0MDEV Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Ruxolitinib + Epirubicin DC2T6FS Ruxolitinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Ruxolitinib + Epirubicin DC4OPDA Ruxolitinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Ruxolitinib + Epirubicin DC61QER Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Ruxolitinib + Epirubicin DCOJOF7 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Ruxolitinib + Epirubicin DC5WXRQ Ruxolitinib Adenocarcinoma (Cell Line: DU-145) [4]
Ruxolitinib + Epirubicin DCY711Y Ruxolitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Ruxolitinib + Epirubicin DCQB6TH Ruxolitinib Adenocarcinoma (Cell Line: HCT116) [4]
Ruxolitinib + Epirubicin DCFK8Q3 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Ruxolitinib + Epirubicin DCM00OP Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Ruxolitinib + Epirubicin DCMB7NV Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Ruxolitinib + Epirubicin DC80N1V Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Ruxolitinib + Epirubicin DC4OMHK Ruxolitinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Ruxolitinib + Epirubicin DC84JJZ Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Ruxolitinib + Epirubicin DC7YJU6 Ruxolitinib Melanoma (Cell Line: UACC-257) [4]
Ruxolitinib + Epirubicin DCCYMY0 Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Epirubicin DCDU302 Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Epirubicin DCFJO2Z Vandetanib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Epirubicin DCO1IBA Vandetanib Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Epirubicin DCMSMOY Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Epirubicin DCACGPO Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Epirubicin DCGDF41 Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Epirubicin DC4GD6E Vandetanib Astrocytoma (Cell Line: U251) [4]
Vandetanib + Epirubicin DCHCBZK Vandetanib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Epirubicin DC04ZAW Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Epirubicin DC7QPEM Vandetanib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Epirubicin DCINPL5 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Epirubicin DCVOAU1 Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Epirubicin DCFOMNA Vandetanib Glioma (Cell Line: SF-268) [4]
Vandetanib + Epirubicin DC3Z03J Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Epirubicin DCADFLR Vandetanib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Epirubicin DC7XRQC Vandetanib Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Epirubicin DCEB7K7 Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Epirubicin DCUTNDS Vandetanib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Epirubicin DCIYBKB Vandetanib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vemurafenib + Epirubicin DCU854C Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vemurafenib + Epirubicin DCB5JAJ Vemurafenib Carcinoma (Cell Line: RXF 393) [3]
Vemurafenib + Epirubicin DC7O15X Vemurafenib Carcinoma (Cell Line: MCF7) [3]
Vemurafenib + Epirubicin DCIEB7D Vemurafenib Colon carcinoma (Cell Line: KM12) [3]
Vemurafenib + Epirubicin DC7EGAS Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vemurafenib + Epirubicin DCFAV03 Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vemurafenib + Epirubicin DCNH9RJ Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vemurafenib + Epirubicin DCYHRRL Vemurafenib Adenocarcinoma (Cell Line: DU-145) [4]
Vemurafenib + Epirubicin DCD3UUG Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Vemurafenib + Epirubicin DC6PDQ1 Vemurafenib Adenocarcinoma (Cell Line: NCIH23) [4]
Vemurafenib + Epirubicin DCVMAQO Vemurafenib Adenocarcinoma (Cell Line: A549) [4]
Vemurafenib + Epirubicin DC8JDUS Vemurafenib Adenocarcinoma (Cell Line: HCT116) [4]
Vemurafenib + Epirubicin DCKEGKZ Vemurafenib Adenocarcinoma (Cell Line: HCT-15) [4]
Vemurafenib + Epirubicin DCAFV6K Vemurafenib Adenocarcinoma (Cell Line: SW-620) [4]
Vemurafenib + Epirubicin DC7SNBR Vemurafenib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vemurafenib + Epirubicin DCA8BQF Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vemurafenib + Epirubicin DCIUQEC Vemurafenib Astrocytoma (Cell Line: U251) [4]
Vemurafenib + Epirubicin DCEXFZK Vemurafenib Astrocytoma (Cell Line: SNB-19) [4]
Vemurafenib + Epirubicin DCZ145J Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vemurafenib + Epirubicin DCHHSHW Vemurafenib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vemurafenib + Epirubicin DCYJTYD Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vemurafenib + Epirubicin DCIXJZ2 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vemurafenib + Epirubicin DCXU1CI Vemurafenib Glioma (Cell Line: SF-268) [4]
Vemurafenib + Epirubicin DCMOTMH Vemurafenib Glioma (Cell Line: SF-539) [4]
Vemurafenib + Epirubicin DCR2YYE Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vemurafenib + Epirubicin DCMC9C8 Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vemurafenib + Epirubicin DC6X8TI Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vemurafenib + Epirubicin DC7VHXT Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vemurafenib + Epirubicin DCCS9KD Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vemurafenib + Epirubicin DC77I6D Vemurafenib Lung adenocarcinoma (Cell Line: EKVX) [4]
Vemurafenib + Epirubicin DC13R21 Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vemurafenib + Epirubicin DCEBSQJ Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vemurafenib + Epirubicin DCV84ER Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vemurafenib + Epirubicin DCYC6FW Vemurafenib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vemurafenib + Epirubicin DCK3R4I Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vemurafenib + Epirubicin DCKORDW Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vemurafenib + Epirubicin DC939ZS Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vemurafenib + Epirubicin DCSOMCH Vemurafenib Prostate carcinoma (Cell Line: PC-3) [4]
Vemurafenib + Epirubicin DCA82QP Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [4]
Vismodegib + Epirubicin DC9UWAB Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vismodegib + Epirubicin DCX7ZQE Vismodegib Carcinoma (Cell Line: RXF 393) [3]
Vismodegib + Epirubicin DCP61QW Vismodegib Carcinoma (Cell Line: MCF7) [3]
Vismodegib + Epirubicin DCOPWL3 Vismodegib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vismodegib + Epirubicin DCYJXEP Vismodegib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vismodegib + Epirubicin DC598EZ Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vismodegib + Epirubicin DCNGIQQ Vismodegib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vismodegib + Epirubicin DCFRAKY Vismodegib Adenocarcinoma (Cell Line: DU-145) [4]
Vismodegib + Epirubicin DCK8UGB Vismodegib Adenocarcinoma (Cell Line: NCIH23) [4]
Vismodegib + Epirubicin DCBQVDZ Vismodegib Adenocarcinoma (Cell Line: A549) [4]
Vismodegib + Epirubicin DCNEOAT Vismodegib Adenocarcinoma (Cell Line: HCT-15) [4]
Vismodegib + Epirubicin DCA1NCN Vismodegib Adenocarcinoma (Cell Line: HT29) [4]
Vismodegib + Epirubicin DC7ZX63 Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vismodegib + Epirubicin DCF6SP6 Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vismodegib + Epirubicin DCR06DQ Vismodegib Amelanotic melanoma (Cell Line: M14) [4]
Vismodegib + Epirubicin DCH9GNK Vismodegib Astrocytoma (Cell Line: U251) [4]
Vismodegib + Epirubicin DCM43HH Vismodegib Astrocytoma (Cell Line: SNB-19) [4]
Vismodegib + Epirubicin DCQ41NK Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vismodegib + Epirubicin DCN8098 Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vismodegib + Epirubicin DCWXLR7 Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vismodegib + Epirubicin DCNXPY4 Vismodegib Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vismodegib + Epirubicin DCKH2YP Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vismodegib + Epirubicin DCUF09T Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vismodegib + Epirubicin DC5G1HL Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vismodegib + Epirubicin DCV4U5M Vismodegib Glioblastoma (Cell Line: SNB-75) [4]
Vismodegib + Epirubicin DCSGM2H Vismodegib Glioma (Cell Line: SF-539) [4]
Vismodegib + Epirubicin DCJVC08 Vismodegib Glioma (Cell Line: SF-268) [4]
Vismodegib + Epirubicin DCEPA15 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vismodegib + Epirubicin DCZZ5D3 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vismodegib + Epirubicin DC8LIFS Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vismodegib + Epirubicin DCI07LH Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vismodegib + Epirubicin DCYM41D Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vismodegib + Epirubicin DCMTKNG Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [4]
Vismodegib + Epirubicin DCLQ3SG Vismodegib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vismodegib + Epirubicin DC5YKLH Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vismodegib + Epirubicin DCW4OB8 Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vismodegib + Epirubicin DCY5Y54 Vismodegib Melanoma (Cell Line: SK-MEL-2) [4]
Vismodegib + Epirubicin DCTXDAR Vismodegib Melanoma (Cell Line: UACC-257) [4]
Vismodegib + Epirubicin DCW97TN Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vismodegib + Epirubicin DCZB598 Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vismodegib + Epirubicin DCPM68T Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vismodegib + Epirubicin DCBVMLB Vismodegib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vismodegib + Epirubicin DCAFIHJ Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1142 DrugCom(s)
14 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Docetaxel + Epirubicin DCR7L6G Docetaxel Breast Cancer [5]
Epirubicin + Oxaliplatin DC7H2DD Oxaliplatin Esophageal Cancer [6]
Ixabepilone + Epirubicin DCBITL6 Ixabepilone Metastatic Breast Cancer [7]
Paclitaxel + Epirubicin DCG4V5F Paclitaxel Metastatic Breast Cancer [8]
Paclitaxel + Epirubicin DC2I73T Paclitaxel Metastatic Breast Cancer [8]
Pazopanib + Epirubicin DCFHKL4 Pazopanib Neoplasms, Breast [9]
Docetaxel + Epirubicin DCR841C Docetaxel Breast Neoplasms [10]
Epirubicin + Oxaliplatin DC3EN7P Oxaliplatin Gastric Cancer [11]
Epirubicin + Oxaliplatin DC7PRHQ Oxaliplatin Esophageal Neoplasms [12]
Epirubicin + Oxaliplatin DCDNBR7 Oxaliplatin CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction [13]
Epirubicin + Oxaliplatin DCRNVB3 Oxaliplatin Gastro Oesophageal Cancer [14]
Docetaxel + Epirubicin DC11HNK Docetaxel Breast Cancer [15]
Epirubicin + Oxaliplatin DCEWIV9 Oxaliplatin Gastric Cancer [16]
Docetaxel + Epirubicin DCSZAA6 Docetaxel Breast Cancer [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DrugCom(s)

References

1 New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT00424606) Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
6 ClinicalTrials.gov (NCT01386346) Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
7 ClinicalTrials.gov (NCT00322374) Phase I Combination w/ Epirubicin
8 ClinicalTrials.gov (NCT01433614) Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer
9 ClinicalTrials.gov (NCT00722293) A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
10 ClinicalTrials.gov (NCT02307227) Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
11 ClinicalTrials.gov (NCT00454636) A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
12 ClinicalTrials.gov (NCT02177552) Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
13 ClinicalTrials.gov (NCT01630083) Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
14 ClinicalTrials.gov (NCT01710592) A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
15 ClinicalTrials.gov (NCT00540800) BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
16 ClinicalTrials.gov (NCT02395640) The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
17 ClinicalTrials.gov (NCT03123770) Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients